Beryl Drugs Ltd

Beryl Drugs' historical performance shows fluctuating financial metrics, with net sales peaking at 26.89 Cr in Mar'23 but declining to 21.15 Cr by Mar'25, while total operating income also fell from 27.16 Cr to 22.56 Cr in the same period. Despite a decrease in profits and total assets, cash flow from operating activities improved to 2.00 Cr in Mar'25.

As of 29-Oct, Beryl Drugs Ltd's stock price is Rs 24.00, up 4.35% recently, but it has a significant year-to-date decline of 33.61%. Despite short-term gains, investor participation has dropped notably, indicating potential concerns about sustained interest.

As of 07-Oct, Beryl Drugs Ltd's stock price is Rs 22.75, down 5.17%, and has underperformed its sector by 5.48%. The stock has a year-to-date decline of 37.07% and lacks identifiable catalysts for its current downward trend.

As of 06-Oct, Beryl Drugs Ltd is currently priced at 23.99, reflecting a 2.3% increase. The stock has shown strong short-term performance, gaining 7.82% over the past week, although it remains down 33.64% year-to-date compared to the Sensex's rise.

As of 26-Sep, Beryl Drugs Ltd's stock price has declined to Rs 22.39, down 5.73%, with a total loss of 7.44% over the last two days. The stock has underperformed its sector and shows a bearish trend, with significant drops in investor participation and a year-to-date decline of 38.06%.

As of 24-Sep, Beryl Drugs Ltd is seeing a price increase to Rs 24.24, up 5.39%, and has outperformed its sector recently. However, it has a significant year-to-date decline of -32.95%, indicating weak long-term fundamentals despite recent gains.

As of 23-Sep, Beryl Drugs Ltd is currently priced at 23.00, reflecting a short-term increase but a significant year-over-year decline of -36.11%. Despite attractive valuations, the company faces long-term challenges that may deter investors.

As of 22-Sep, Beryl Drugs Ltd is currently priced at 22.98, reflecting a slight increase today but a significant year-to-date decline of 36.43%. Despite recent underperformance compared to the Sensex, the stock has shown strong long-term growth, outperforming the benchmark over the past three years.

As of 19-Sep, Beryl Drugs Ltd's stock price is declining at 22.61, down 4.07%, with a year-to-date return of -37.46%. The company is underperforming its sector and the broader market, reflecting weak fundamentals and declining investor interest.

As of 18-Sep, Beryl Drugs Ltd is currently priced at 23.57, reflecting a recent upward trend despite poor long-term performance, with year-to-date returns of -34.80%. The stock has shown short-term gains but underperformed the broader market significantly over the past year.

As of 17-Sep, Beryl Drugs Ltd's stock price is at 23.00, down 3.6%, and has declined 5.35% over the last three days. Despite an attractive valuation, the stock's profits have decreased by 37% over the past year, leading to underperformance compared to the market.

As of 16-Sep, Beryl Drugs Ltd's stock price is at 23.86, down 1.49%, and has underperformed its sector. The stock has a poor annual return of -36.12% and faces challenges with declining profits and weak long-term fundamentals.

As of 15-Sep, Beryl Drugs Ltd's stock price is at 24.22, down 0.33%, and has underperformed significantly over the past year with a return of -37.67%. Despite an attractive valuation, weak fundamentals and concerns over debt servicing contribute to cautious investor sentiment.

As of 12-Sep, Beryl Drugs Ltd is seeing a price increase to 24.30, up 2.1%, but faces concerns over declining investor participation with a significant drop in delivery volume. Despite strong recent performance, the stock's year-to-date decline of -32.78% suggests cautious investor sentiment.

As of 11-Sep, Beryl Drugs Ltd's stock price is declining at 23.80, down 1.49%, with significant drops in delivery volume and a year-to-date return of -34.16%. The company's weak fundamentals and underperformance compared to the market indicate declining investor interest.

As of 10-Sep, Beryl Drugs Ltd is priced at 24.16, showing a slight increase but significantly underperforming with a -40.32% return over the past year. Weak long-term fundamentals and declining investor interest indicate that negative factors are currently outweighing any positive price movements.

As of 09-Sep, Beryl Drugs Ltd's stock price is 24.12, down 2.94%, with a significant decline in delivery volume and a 45.14% drop over the past year, indicating weak long-term fundamentals and poor investor participation. In contrast, the broader market has shown positive returns, highlighting Beryl's underperformance.

As of 08-Sep, Beryl Drugs Ltd is seeing a price increase to 24.85, up 3.5%, but has underperformed recently with a 1-week return of -6.23%. Despite today's gains, weak long-term fundamentals and a significant decline in investor participation raise concerns for potential investors.